Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients
Sponsor: AEterna Zentaris
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from AEterna Zentaris
Listed as NCT01002248, this PHASE3 trial focuses on Multiple Myeloma and remains terminated or withdrawn. Sponsored by AEterna Zentaris, it has been updated 9 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Apr 2022 — Jul 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Apr 2022 [monthly]
Terminated PHASE3
▶ Show 4 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Terminated PHASE3
-
Feb 2017 — Mar 2018 [monthly]
Terminated PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE3
First recorded
Dec 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AEterna Zentaris
- Dana-Farber Cancer Institute
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Afula, Israel , Ashkelon, Israel , Aurora, United States , Badalona, Spain , Baltimore, United States , Barcelona, Spain , Bedford, United States , Beersheba, Israel , Boston, United States , Boulder, United States and 61 more locations